Abstract
Objectives: This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:. To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance. Review question What are the perspectives and experiences of people providing and receiving low-complexity NAATs to diagnose tuberculosis and tuberculosis drug resistance? Answering this question will allow us to identify the implications for effective implementation and health equity.
| Original language | English |
|---|---|
| Article number | CD014877 |
| Journal | Cochrane Database of Systematic Reviews |
| Volume | 2021 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 3 Sept 2021 |
Access to Document
- 10.1002/14651858.CD014877Licence: Unspecified
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Cochrane Database of Systematic Reviews, Vol. 2021, No. 9, CD014877, 03.09.2021.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Rapid molecular tests for tuberculosis and tuberculosis drug resistance
T2 - provider and recipient views
AU - Engel, Nora
AU - Ochodo, Eleanor A.
AU - Karanja, Perpetua Wanjiku
AU - Schmidt, Bey-Marrié
AU - Janssen, Ricky
AU - Steingart, karen R.
AU - Oliver, Sandy
N1 - Funding Information: The editorial base of the Cochrane Infectious Diseases Group (CIDG) is funded by UK aid from the UK government for the benefit of low-and middle-income countries (project number 300342-104). The views expressed do not necessarily reflect the UK government’s official policies. We are grateful to Vittoria Lutje, CIDG Information Specialist, for helping us with the search strategy. Funding Information: KRS: received funding from the World Health Organization (WHO) Global Tuberculosis Programme, Switzerland. Received additional financial support from Cochrane Infectious Diseases, UK; McGill University, Canada; Baylor College of Medicine, Houston; and the World Health Organization Global Tuberculosis Programme, Switzerland, for the preparation of related systematic reviews and educational materials; consultancy fees from Foundation for Innovative New Diagnostics (FIND), Switzerland (for the preparation of systematic reviews and GRADE tables); consultancy fees from Stellenbosch University, Stellenbosch (for guidance on evidence syntheses); and honoraria and travel support to attend WHO guideline meetings. Funding Information: This work was partly supported through a grant from the WHO Global Tuberculosis Programme, Agreement for Performance of Work (APW) (registration number 202582434). The views expressed in this review have not been influenced by, or necessarily reflect, WHO policy. Funding Information: We acknowledge the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Effective Practice and Organisation of Care (EPOC) Group. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health. Funding Information: SO: received funding from the READ-It programme, UK (project number 300342-104). Funding Information: The Academic Editor is Professor Paul Garner, and Sign-off Editor is Dr Hellen Gelband. The editorial base of the Cochrane Infectious Diseases Group (CIDG) is funded by UK aid from the UK government for the benefit of low- and middle-income countries (project number 300342-104). The views expressed do not necessarily reflect the UK government?s official policies. We are grateful to Vittoria Lutje, CIDG Information Specialist, for helping us with the search strategy. We acknowledge the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Effective Practice and Organisation of Care (EPOC) Group. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health. This work was partly supported through a grant from the WHO Global Tuberculosis Programme,?Agreement for Performance of Work (APW) (registration number 202582434). The views?expressed in this review have not been influenced by, or necessarily reflect, WHO policy. Publisher Copyright: Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2021/9/3
Y1 - 2021/9/3
N2 - Objectives: This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:. To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance. Review question What are the perspectives and experiences of people providing and receiving low-complexity NAATs to diagnose tuberculosis and tuberculosis drug resistance? Answering this question will allow us to identify the implications for effective implementation and health equity.
AB - Objectives: This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:. To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance. Review question What are the perspectives and experiences of people providing and receiving low-complexity NAATs to diagnose tuberculosis and tuberculosis drug resistance? Answering this question will allow us to identify the implications for effective implementation and health equity.
U2 - 10.1002/14651858.CD014877
DO - 10.1002/14651858.CD014877
M3 - Article
SN - 1469-493X
VL - 2021
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 9
M1 - CD014877
ER -